TX-MAVENIR
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announces that its world-leading SpamShield messaging fraud prevention technology is driving a steep decline in the volume of spam and scam messages for Globe Telecom, Inc. in the Philippines – demonstrating its ability to disincentivize scammers and successfully boost customer protection against fraudulent, malicious and nuisance messaging. The Philippines is one of the large SMS markets in the world, and addressing the aggressive growth in the volume of spam and scam messaging is a key priority for the government’s National Telecommunications Commission (NTC).
In an impressive year-on-year improvement, Mavenir’s SpamShield has enabled the Philippines’ largest mobile operator to achieve a record 67% drop in blocked spam and scam SMS, plus a 74% decline in bank-related spam and scam messages during the first quarter of 2024, compared with the same period in 2023. The total number of blocked spam and scam SMS messages fell substantially from 1.1 billion in Q1 2023 to 362.8 million in Q1 2024. Over the same time span, the number of scam SMS messages directly reported by customers declined 44% year-on-year – from 610 in Q1 2023 to 342 in Q1 2024. Mavenir’s SpamShield technology has delivered an immediate and measurable impact for Globe – which reported blocking over 5 billion spam and scam messages in 2023 – by significantly raising the technical barriers to send fraudulent campaigns, increasing the cost of fraud, and removing profit incentives for scammers.
Mavenir’s SpamShield operates as a powerful SMS firewall – incorporating advanced monitoring, adaptive analytics, and real-time machine learning (ML) capabilities – that empowers Communication Service Providers (CSPs) to automatically block millions of fraudulent messages before they ever reach subscribers. SpamShield’s AI/ML detection algorithms adapt to current network conditions and subscriber behavior to continually detect spammer and fraudster attempts – enabling CSPs to quickly identify and act on potential threats and harmful events. This unique and innovative solution delivers an improved experience and greater security for customers, while protecting CSPs’ revenues from the negative costs of malicious activity.
Commenting on its successful spam reduction initiative, Anton Bonifacio, Chief Information Security Officer for Globe said: “Mavenir’s SpamShield technology has proven its ability to offer timely, precise, and effective threat detection and response, playing a central role in this dramatic reduction of spam and scam SMS traffic across our network to the immense benefit of all our customers. We now consider SpamShield an essential component of Globe’s anti-spam strategy moving forward, as we increase our innovation investment and strengthen our defenses against the tide of increasingly sophisticated fraudulent activity.”
Ilia Abramov, VP & GM of the Security Business Unit at Mavenir added: “Globe’s implementation of our SpamShield technology underlines its stringent and highly proactive approach to safeguarding customers, protecting users through the most robust and intelligent anti-spam messaging solution available today. The massive drop in blocked messages evidenced by these remarkable numbers shows how SpamShield achieves its transformative results in operation – making fraudulent activity prohibitively difficult and unprofitable for scammers, who then move on to easier and less protected targets including other operators and OTT channels such as WhatsApp. Globe is at the forefront of industry efforts to protect subscribers from this growing and ever-evolving array of threats, and we will continue to vigorously support its efforts to optimize communication safety and messaging authenticity in the Philippines.”
Notes to editors:
- Combating Messaging Scam and Fraud: A Telecom TV panel session with Globe recorded at MWC24: https://www.mavenir.com/resources/combating-messaging-scam-and-fraud/
About Globe:
Globe Telecom, Inc. is a leading full-service telecommunications company in the Philippines and publicly listed in the PSE with the stock symbol GLO. The company serves the telecommunications and technology needs of consumers and businesses across an entire suite of products and services including mobile, fixed, broadband, data connectivity, internet and managed services. It offers innovative digital solutions in the areas of fintech, healthtech, adtech, climatetech, shared services and venture capital. In 2019, Globe became a signatory to the United Nations Global Compact, committing to implement universal sustainability principles. Its principals are Ayala Corporation and Singtel, acknowledged industry leaders in the country and in the region.
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240529690737/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
